
This is according to spokesperson, Mark van der Heever, who also said they would only begin implementation once sufficient stock is available.
“Clinical training of staff also has to be conducted and educating patients on the use of it must still commence; thus the transitioning of all patients on to DTG will not happen immediately when the province receives the stock,” he said.
DTG was recently approved by the World Health Organisation (WHO), after preliminary results of a 96-week trial, that was conducted by a Joburg-based research group from the University of the Witwatersrand.
The drug was discussed at the International Aids Conference on July 24 in Mexico City.